What we found on the web about Avastin
Bevacizumab - Wikipedia, the free encyclopedia
Bevacizumab (trade name Avastin, Genentech / Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF). [1]
Oxaliplatin - Wikipedia, the free encyclopedia
Oxaliplatin is a platinum-based cancer chemotherapy drug. [2] These drugs are usually classified as alkylating agents, although they are not capable of actually adding alkyl groups ...
Lucentis Vs. Avastin for Treating Macular Degeneration
Lucentis has been FDA-approved for treating macular degeneration, but some eye doctors say Avastin may be an equally effective and much cheaper alternative.
Avastin, Bevacizumab - Chemotherapy Drugs, Chemo Side Effects
Avastin is a chemotherapy drug used to treat colon, rectal and lung cancer. Another name for chemo drug Avastin is Bevacizumab. Learn more about cancer treatment and the side ...
Comparison of Age-Related Macular Degeneration Treatments Trials ...
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on ...
Genentech: Pipeline: Avastin
Description Avastin® (bevacizumab) is a recombinant humanized antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an ...
Age Related Macular Degeneration: Avastin
A number of ophthalmologists who specialize in retinal disease have been writing and asking about Avastin® (bevacizumab), which was covered in the Sept 19th blog.
The Evidence Gap - In Cost Cancer Drug Avastin, Hope and a Dilemma ...
Avastin, which can cost as much as $100,000 a year, has become one of the most popular cancer drugs, but studies show it prolongs life by only a few months.
Avastin - OrganizedWisdom Health
Avastin is a brand name for the drug bevacizumab. It is a drug treatment for metastatic colon cancer, metastatic rectal cancer, metastatic breast cancer, and recurrent or ...
Roche - Product-details: Avastin (Bevacizumab)
Indicated in combination with chemotherapy for the treatment of advanced colorectal, breast, and lung cancer and in combination with interferon alfa for advanced renal cell cancer.
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about Avastin

Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF). VEGF is a chemical signal that stimulates the growth of new blood vessels (angiogenesis).

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Avastin
Clinton, Pfizer and Mylan announce deal to lower cost of HIV drugs in ...
Chicago Tribune
A recall of nuts that could be contaminated with listeria has been traced to a California plant, and a small number of those nuts made their way to consumers, John B. Sanfilippo & Son Inc. said Wednesday in a filing with federal securities ...
Dendreon Recruits Genentech CEO, Former Lilly Manufacturing Chief to ...
Xconomy
Clark was in charge of commercial operations at Genentech when it was the largest U.S. maker of cancer drugs, marketing blockbusters like bevacizumab (Avastin), and trastuzumab (Herceptin). He is now CEO of the Genentech unit in South San F...
Avastin OK'd for Advanced Breast Cancer
MedicineNet.com
Breast Cancer Monitoring Innovations Liver Cancer Patients May Get Hope Colon Cancer Vaccine Coming Soon? Many Childhood Cancer Survivors Never Marry Gene Test Might Predict Tamoxifen's Effectiveness Want More News? Sign Up for MedicineNet ...
PHARMA'S MARKET VIDEO
CNBC
Geoffrey Meacham at JPMorgan says if that Avastin study goes well that Genentech shares could be worth more than a hundred bucks. "We do not expect the majority of shareholders to participate in this tender offer, where most of the core hol...
Swiss Stocks Advance, Led by ABB, Actelion, Zurich Financial
Bloomberg
ABB Ltd., the world’s largest builder of electricity networks, and Roche Holding AG, maker of the Avastin cancer drug, paced gains in the Swiss Market Index. Actelion Ltd. rose after JPMorgan Chase & Co. advised buying the shares. The SMI, ...
Register for FREE
Wall Street Journal
Newer drugs such as Avastin are designed to home in on tumor cells, in Avastin's case by blocking the growth of new blood vessels that feed tumor growth. Even some forms of chemotherapy can be programmed to be more targeted—the drug Doxil, ...
Roche sales beat forecasts, ups Tamiflu guidance
MSN Money
Blockbuster cancer drug Avastin also underpinned growth, with nine-month sales up 26 percent. Roche sees Tamiflu revenue of 2.7 billion francs, versus previous guidance of 2 billion. The group repaid 7 billion francs of debt from its Genent...
Medicare would shift patients off $50 drug to $2,000
San Francisco Gate
Because drugs like Avastin and Genentech are bought exclusively by physicians - who inject them into patients in the office - the issue would not directly impact consumer costs. A spokeswoman for Genentech said the company has not discussed...
Dendreon Announces Election of Ian Clark and Pedro Granadillo to
MSN Money
... vice president of commercial operations and senior vice president of oncology commercial operations for Genentech's BioOncology business unit, which focused on global commercialization of the company's diverse oncology pipeline, includi...
Genentech timeline
San Francisco Gate
2004: The FDA approves Genentech's Avastin for colon cancer and Tarceva for lung cancer. March 12: After months of haggling over price, Genentech accepts an offer of $95 per share to be acquired by majority shareholder Roche and become a pr...